Cargando…

Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease

BACKGROUND: The current diagnosis of Alzheimer’s disease (AD) is based on a series of analyses which involve clinical, instrumental and laboratory findings. However, signs, symptoms and biomarker alterations observed in AD might overlap with other dementias, resulting in misdiagnosis. METHODS: Here...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Andrea, Cristiano, Cazzaniga, Federico Angelo, Bistaffa, Edoardo, Barucci, Andrea, de Angelis, Marella, Banchelli, Martina, Farnesi, Edoardo, Polykretis, Panagis, Marzi, Chiara, Indaco, Antonio, Tiraboschi, Pietro, Giaccone, Giorgio, Matteini, Paolo, Moda, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337059/
https://www.ncbi.nlm.nih.gov/pubmed/37438825
http://dx.doi.org/10.1186/s40035-023-00367-9
_version_ 1785071336092073984
author D’Andrea, Cristiano
Cazzaniga, Federico Angelo
Bistaffa, Edoardo
Barucci, Andrea
de Angelis, Marella
Banchelli, Martina
Farnesi, Edoardo
Polykretis, Panagis
Marzi, Chiara
Indaco, Antonio
Tiraboschi, Pietro
Giaccone, Giorgio
Matteini, Paolo
Moda, Fabio
author_facet D’Andrea, Cristiano
Cazzaniga, Federico Angelo
Bistaffa, Edoardo
Barucci, Andrea
de Angelis, Marella
Banchelli, Martina
Farnesi, Edoardo
Polykretis, Panagis
Marzi, Chiara
Indaco, Antonio
Tiraboschi, Pietro
Giaccone, Giorgio
Matteini, Paolo
Moda, Fabio
author_sort D’Andrea, Cristiano
collection PubMed
description BACKGROUND: The current diagnosis of Alzheimer’s disease (AD) is based on a series of analyses which involve clinical, instrumental and laboratory findings. However, signs, symptoms and biomarker alterations observed in AD might overlap with other dementias, resulting in misdiagnosis. METHODS: Here we describe a new diagnostic approach for AD which takes advantage of the boosted sensitivity in biomolecular detection, as allowed by seed amplification assay (SAA), combined with the unique specificity in biomolecular recognition, as provided by surface-enhanced Raman spectroscopy (SERS). RESULTS: The SAA-SERS approach supported by machine learning data analysis allowed efficient identification of pathological Aβ oligomers in the cerebrospinal fluid of patients with a clinical diagnosis of AD or mild cognitive impairment due to AD. CONCLUSIONS: Such analytical approach can be used to recognize disease features, thus allowing early stratification and selection of patients, which is fundamental in clinical treatments and pharmacological trials. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40035-023-00367-9.
format Online
Article
Text
id pubmed-10337059
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103370592023-07-13 Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease D’Andrea, Cristiano Cazzaniga, Federico Angelo Bistaffa, Edoardo Barucci, Andrea de Angelis, Marella Banchelli, Martina Farnesi, Edoardo Polykretis, Panagis Marzi, Chiara Indaco, Antonio Tiraboschi, Pietro Giaccone, Giorgio Matteini, Paolo Moda, Fabio Transl Neurodegener Research BACKGROUND: The current diagnosis of Alzheimer’s disease (AD) is based on a series of analyses which involve clinical, instrumental and laboratory findings. However, signs, symptoms and biomarker alterations observed in AD might overlap with other dementias, resulting in misdiagnosis. METHODS: Here we describe a new diagnostic approach for AD which takes advantage of the boosted sensitivity in biomolecular detection, as allowed by seed amplification assay (SAA), combined with the unique specificity in biomolecular recognition, as provided by surface-enhanced Raman spectroscopy (SERS). RESULTS: The SAA-SERS approach supported by machine learning data analysis allowed efficient identification of pathological Aβ oligomers in the cerebrospinal fluid of patients with a clinical diagnosis of AD or mild cognitive impairment due to AD. CONCLUSIONS: Such analytical approach can be used to recognize disease features, thus allowing early stratification and selection of patients, which is fundamental in clinical treatments and pharmacological trials. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40035-023-00367-9. BioMed Central 2023-07-12 /pmc/articles/PMC10337059/ /pubmed/37438825 http://dx.doi.org/10.1186/s40035-023-00367-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
D’Andrea, Cristiano
Cazzaniga, Federico Angelo
Bistaffa, Edoardo
Barucci, Andrea
de Angelis, Marella
Banchelli, Martina
Farnesi, Edoardo
Polykretis, Panagis
Marzi, Chiara
Indaco, Antonio
Tiraboschi, Pietro
Giaccone, Giorgio
Matteini, Paolo
Moda, Fabio
Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease
title Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease
title_full Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease
title_fullStr Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease
title_full_unstemmed Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease
title_short Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease
title_sort impact of seed amplification assay and surface-enhanced raman spectroscopy combined approach on the clinical diagnosis of alzheimer’s disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337059/
https://www.ncbi.nlm.nih.gov/pubmed/37438825
http://dx.doi.org/10.1186/s40035-023-00367-9
work_keys_str_mv AT dandreacristiano impactofseedamplificationassayandsurfaceenhancedramanspectroscopycombinedapproachontheclinicaldiagnosisofalzheimersdisease
AT cazzanigafedericoangelo impactofseedamplificationassayandsurfaceenhancedramanspectroscopycombinedapproachontheclinicaldiagnosisofalzheimersdisease
AT bistaffaedoardo impactofseedamplificationassayandsurfaceenhancedramanspectroscopycombinedapproachontheclinicaldiagnosisofalzheimersdisease
AT barucciandrea impactofseedamplificationassayandsurfaceenhancedramanspectroscopycombinedapproachontheclinicaldiagnosisofalzheimersdisease
AT deangelismarella impactofseedamplificationassayandsurfaceenhancedramanspectroscopycombinedapproachontheclinicaldiagnosisofalzheimersdisease
AT banchellimartina impactofseedamplificationassayandsurfaceenhancedramanspectroscopycombinedapproachontheclinicaldiagnosisofalzheimersdisease
AT farnesiedoardo impactofseedamplificationassayandsurfaceenhancedramanspectroscopycombinedapproachontheclinicaldiagnosisofalzheimersdisease
AT polykretispanagis impactofseedamplificationassayandsurfaceenhancedramanspectroscopycombinedapproachontheclinicaldiagnosisofalzheimersdisease
AT marzichiara impactofseedamplificationassayandsurfaceenhancedramanspectroscopycombinedapproachontheclinicaldiagnosisofalzheimersdisease
AT indacoantonio impactofseedamplificationassayandsurfaceenhancedramanspectroscopycombinedapproachontheclinicaldiagnosisofalzheimersdisease
AT tiraboschipietro impactofseedamplificationassayandsurfaceenhancedramanspectroscopycombinedapproachontheclinicaldiagnosisofalzheimersdisease
AT giacconegiorgio impactofseedamplificationassayandsurfaceenhancedramanspectroscopycombinedapproachontheclinicaldiagnosisofalzheimersdisease
AT matteinipaolo impactofseedamplificationassayandsurfaceenhancedramanspectroscopycombinedapproachontheclinicaldiagnosisofalzheimersdisease
AT modafabio impactofseedamplificationassayandsurfaceenhancedramanspectroscopycombinedapproachontheclinicaldiagnosisofalzheimersdisease